SVB Leerink started coverage on shares of Repare Therapeutics (NASDAQ:PAND) in a research note issued to investors on Tuesday morning, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $24.00 target price on the stock. SVB Leerink also issued estimates for Repare Therapeutics’ Q2 2020 earnings at ($0.93) EPS, Q3 2020 earnings at ($0.42) EPS, Q4 2020 earnings at ($0.49) EPS, FY2020 earnings at ($2.23) EPS, FY2021 earnings at ($1.94) EPS, FY2022 earnings at ($2.04) EPS, FY2023 earnings at ($2.26) EPS and FY2024 earnings at ($2.41) EPS.
A number of other equities analysts have also weighed in on the stock. BMO Capital Markets began coverage on shares of Repare Therapeutics in a research note on Monday. They issued an outperform rating and a $29.00 target price for the company. Goldman Sachs Group started coverage on shares of Repare Therapeutics in a research report on Tuesday. They set a buy rating and a $28.00 price target on the stock.
NASDAQ PAND traded up $0.27 on Tuesday, reaching $18.83. The company had a trading volume of 516 shares, compared to its average volume of 177,296. Repare Therapeutics has a 1-year low of $16.67 and a 1-year high of $27.75.
About Repare Therapeutics
Pandion Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprised of an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases.
Further Reading: How is a management fee different from a performance fee?
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.